In consideration of MR-induced CV inflammation, fibrosis, and remodeling, steroidal mineralocorticoid receptor antagonists (MRAs), as such spironolactone and eplerenone, gained a central role in the treatment of CV conditions associated with RAAS upregulation, as heart failure with reduced ejection fraction (HFrEF) and resistant hypertension. This evidence concerns the gene NR3C2 and Hypertension resistant to conventional therapy.